M. Enriquez

发表

Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover study

M. Morfini, P. Collins, A. Faradji, 2010, Journal of thrombosis and haemostasis : JTH.

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial

C. Pozzilli, F. Fazekas, P. Sørensen, 2004, The Lancet.

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS

J. Windyga, S. Lalezari, U. Martinowitz, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome—The ESSICS study*

F. Mohr, H. Schäfers, L. Thijs, 2008, Critical care medicine.

MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)

M. Filippi, C. Pozzilli, S. Ropele, 2005, Multiple sclerosis.

Patient characteristics that influence efficacy of prophylaxis with rFVIII‐FS three times per week: a subgroup analysis of the LIPLONG study

A. Coppola, S. Lalezari, J. Ingerslev, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients

G. Di Minno, I. Pabinger, J. Windyga, 2012, Thrombosis and Haemostasis.

Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose‐formulated recombinant factor VIII

E. Gorina, G. Lemm, N. Bajwa, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study

M. Morfini, P. Collins, A. Faradji, 2008 .

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit

B. Ploeger, S. Mcleay, Anita Shah, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Postmarketing surveillance study of KOGENATE® Bayer with Bio‐Set® in patients with haemophilia A: evaluation of patients’ satisfaction after switch to the new reconstitution system

R. Klamroth, R. Musso, M. M. Enriquez, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.